Press Release - Vyluma | Ophthalmic Pharmaceutical Solutions

Press Release

VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS

VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA

NEVAKAR AND THÉA ENTER INTO LICENSING AGREEMENT FOR THE COMMERCIALIZATION OF NVK002 (ATROPINE FOR THE TREATMENT OF THE PROGRESSION OF MYOPIA IN CHILDREN) IN EUROPE

American Academy of ophthalmology leads global initiative to address worldwide myopia epidemic

FIRST PATIENT COMPLETES THREE YEAR ENROLLMENT IN NEVAKAR’S PHASE III CHAMP STUDY OF NVK002 EVALUATING LOW-DOSE ATROPINE OPHTHALMIC SOLUTION FOR THE TREATMENT OF MYOPIA IN CHILDREN

Nevakar and zhaoke ophthalmology enter into licensing agreement for nvk002 (atropine for the treatment of the progression of myopia in children)

MyMyopia™ Introduces Infographic for Easy Understanding of Myopia, its Impact, and Treatment Options

Nevakar completes enrollment for its phase iii champ study of nvk002

1019 US Highway 202-206
Building K
NJ Center of Excellence
Bridgewater, NJ 08807

Privacy Policy

Terms & Conditions

mymyopia.com

© 2021 Vyluma